^
    Back
    Association details:
    Biomarker:MET amplification + PIK3CA mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:c-MET inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Front Oncol
    Title:

    Prognosis and Concurrent Genomic Alterations in Patients With Advanced NSCLC Harboring MET Amplification or MET Exon 14 Skipping Mutation Treated With MET Inhibitor: A Retrospective Study

    Published date:
    06/24/2021
    Excerpt:
    ...a statistically significant OS (17.0 months versus 20.0 months, P = 0.044) was only observed in the MET amplification cohort....MET TKIs could be a better treatment option for patients with METex14 skipping mutations. Concurrent mutations may deteriorate the PFS of MET TKIs in NSCLC patients with MET amplification or METex14 skipping mutations. PIK3CA mutations may confer primary resistance to MET TKIs in patients with MET amplification.
    DOI:
    https://doi.org/10.3389/fonc.2021.649766